Primary sites and lactate dehydrogenase level according to stage
| . | Stage I . | Stage II . | Stage III . | Stage IV . | L3ALL . | Total . |
|---|---|---|---|---|---|---|
| Primary site | ||||||
| Abdomen | — | 38 | 230 | 35 (12) | 27 (4) | 330 (16) |
| Head and neck | 10 | 40 | 10 | 17 (13) | 18 (10) | 95 (23) |
| Peripheral node | 17 | 9 | 6 | 2 (1) | 1 (1) | 35 (2) |
| Thorax | — | — | 18 | 1 | 1 | 20 |
| Other sites* | 4 | 1 | 14 | 6 (4) | 1 | 26 (4) |
| Without | 0 | 0 | 0 | 1 (1) | 54 (21) | 55 (22) |
| LDH | ||||||
| ≤ 2N†(%) | 28 (100%) | 80 (95%) | 127 (49%) | 24 (41%) | 3 (3%) | 262 (50%) |
| > 2N (%) | 0 (0%) | 3 (5%) | 132 (51%) | 34 (59%) | 90 (97%) | 258 (50%) |
| Unknown | 3 | 5 | 19 | 4 | 10 | 41 |
| Total | 31 | 88 | 278 | 62 (31) | 102 (36) | 561 (67) |
| . | Stage I . | Stage II . | Stage III . | Stage IV . | L3ALL . | Total . |
|---|---|---|---|---|---|---|
| Primary site | ||||||
| Abdomen | — | 38 | 230 | 35 (12) | 27 (4) | 330 (16) |
| Head and neck | 10 | 40 | 10 | 17 (13) | 18 (10) | 95 (23) |
| Peripheral node | 17 | 9 | 6 | 2 (1) | 1 (1) | 35 (2) |
| Thorax | — | — | 18 | 1 | 1 | 20 |
| Other sites* | 4 | 1 | 14 | 6 (4) | 1 | 26 (4) |
| Without | 0 | 0 | 0 | 1 (1) | 54 (21) | 55 (22) |
| LDH | ||||||
| ≤ 2N†(%) | 28 (100%) | 80 (95%) | 127 (49%) | 24 (41%) | 3 (3%) | 262 (50%) |
| > 2N (%) | 0 (0%) | 3 (5%) | 132 (51%) | 34 (59%) | 90 (97%) | 258 (50%) |
| Unknown | 3 | 5 | 19 | 4 | 10 | 41 |
| Total | 31 | 88 | 278 | 62 (31) | 102 (36) | 561 (67) |
Numbers in parentheses represent patients with CNS involvement.
ALL indicates acute lymphoblastic leukemia; LDH, lactate dehydrogenase.
Other sites include bone, 15; kidney, 5; breast, 1; brain, 2; testis, 1; intraspinal, 1; and subcutaneous, 1.
2N indicates 2-fold the upper limit of the institutional normal.